medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2019, Number 07

<< Back Next >>

Ginecol Obstet Mex 2019; 87 (07)

Evaluation of an antiseptic gel of intravaginal application for multitreated patients for infectious cervicovaginitis

Montesinos-Peña NE, Hernández-Valencia M, Delgado-Enciso I, Herrera-Leal A, Paz-Michel BA

Language: Spanish
References: 34
Page: 454-466
PDF size: 411.86 Kb.


ABSTRACT

Objective: To evaluate the efficacy and safety of an intravaginal antiseptic gel, made of electrolyzed water, against bacterial, yeast, parasitic and mixed cervical infections, and to control typical symptoms in multi-treated patients.
Materials and Methods: Clinical study, comparative with conventional treatment, two arms, multicentric, randomized, with dose escalation carried out in patients attended between May 2017 and May 2018 in the gynecology and obstetrics service of the Hospital General de Ecatepec La Américas, in the Estado de Mexico and the Centro Hospitalario Unión, of Colima. Control group: conventional scheme, antibioticantifungal (7 days); Experimental groups, antiseptic gel for 3, 5 or 10 days. Monitoring of vaginal pH, etiologic agent and symptoms.
Results: 62 multi-treated patients (18-42 years old) were enrolled, presenting bacterial vaginosis 25/62, yeast infection 10/62, trichomoniasis 6/62 or mixed infection 21/62; bacteria and yeast). Treatment with antiseptic gel during 5 or 10 days eradicated etiological agent, respectively in 14/15 patients and 18/20 patients; control treatment did it in 8/14 patients (p = 0.021, p = 0.026, respectively). Additionally, gel treatment for 5 or 10 days was 3 times more effective than control treatment to eradicate the infection, control symptoms and to normalize vaginal pH.
Conclusions: Intravaginal antiseptic gel (5-10 days) was almost 3 times more effective than conventional therapy (antibiotics/antimycotics) against multi-treated cervical infections; as well as useful to control typical symptoms and well tolerated.


REFERENCES

  1. CENETEC. Prevención, Diagnóstico y Tratamiento de la Vaginitis Infecciosa en Mujeres en Edad Reproductiva en el Primer Nivel de Atención. Guía de Práctica Clínica IMSS- 081-08, Consejo de Salubridad General, actualización 2014. www.cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/ 081_GPC_Vaginitisinfec1NA/Vaginitis_ER_CENETEC. pdf> (consultada en marzo 2017).

  2. Faculty of Sexual and Reproductive Healthcare Clinical Guidance. Management of vaginal discharge in nongenitourinary medicine settings. Clinical Effectiveness Unit. BASHH. February 2012. https://www.fsrh.org/ standards-and-guidance/documents/ceu-clinical-guidance- management-of-vaginal-discharge-in-non/1ceu-clinicalguidance- vaginal-discharge-2012-lapsed.pdf> (consultada en marzo 2017).

  3. Workowski KA, Bolan GA. Transmitted Diseases Treatment Guidelines 2015. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. MMWR, Recomendations and Reports, 2015;64 (3). https://www.cdc.gov/mmwr/pdf/rr/rr6403.pdf> (consultada en marzo 2017).

  4. Medina R y col. Prevalencia de vaginitis y vaginosis bacteriana en pacientes con flujo vaginal anormal en el Hospital Nacional Arzobispo Loayza. Rev Med Hered. 1999;10(4):144-50.

  5. Reynaud A. Infecciones vaginales por cándida: diagnóstico y tratamiento. Rev Per Ginecol Obstet. 2007;53(3):159-66.

  6. Sahagún-Cuevas MN, et al. Prevalencia de los gérmenes más frecuentes en pacientes con cervicovaginitis en primer nivel de atención. Revista Médica 2015;6(4):268-72.

  7. Trejo y Pérez JA, et al. Guía Clínica para el Diagnóstico, Tratamiento y Prevención de Cervicovaginitis por bacterias, Trichomonas y Candida. Rev. Med. IMSS. 2003;41 (Supl): S71-S76.

  8. Martínez-Ojeda M, Saldaña-González J, et al. Criterios para el diagnóstico de cervicovaginitis aplicados en el primer nivel de atención. Correlación con la Norma Oficial Mexicana. Rev Med Inst Mex Seguro Soc. 2007;45(3):249-54. http:// www.redalyc.org/articulo.oa?id=457745527007

  9. Sánchez-Hernández JA y col. Cambios en el pH vaginal en pacientes con infección cérvico-vaginal. Enf Inf Microbiol. 2013; 33(2):61-65.

  10. Newman L, et al. Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting. PLoS ONE 2015; 10(12): e0143304. doi: 10.1371/journal. pone.0143304.

  11. López-Hurtado M, y col. Prevalencia de la infección genital por Chlamydia trachomatis en mujeres que asisten al Instituto Nacional de Perinatología de la Ciudad de México. Revista Chilena Infectol. 2018, 35(4):371-76. http://dx.doi. org/10.4067/s0716-10182018000400371

  12. Menard JP. Antibacterial treatment of bacterial vaginosis: current and emerging therapies. Int J of Women’s Health 2011;3:295-305. doi: 10.2147/IJWH.S23814.

  13. Nagaraja P. Antibiotic resistance of Gardnerella vaginalis in recurrent bacterial vaginosis. Indian J Med Microbiol 2008;26:155-7. doi: 10.4103/0255-0857.40531.

  14. Karabicak N, Alem N. Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance. Mikrobiyol Bul. 2016; 50(1):122-32.

  15. Bautista CT, Wurapa E, et al. Bacterial vaginosis: a synthesis of the literature on etiology, prevalence, risk factors, and relationship with chlamydia and gonorrhea infections. Military Medical Research 2016; 3(4):1-10. https://doi. org/10.1186/s40779-016-0074-5

  16. Huan Lu, et al. Characteristics of bacterial vaginosis infection in cervical lesions with risk human papillomavirus infection. Int J Clin Exp Med 2015; 8(11):21080-88. PMID: 26885039

  17. Torres-Capetillo E, et al. Antimicrobial efficacy of neutral super-oxidized electrolyzed gel versus chlorhexidine digluconate 0.12% in biofilm formation on orthodontic mini-implants: An in vitro study. J Pharmacognosy and Phytotherapy, 2013, 5(4):64-71. doi: 10.5897/JPP12.063.

  18. Sosa LO, et al. Prótesis faciales retenidas con implantes e imanes: Presentación de tres casos clínicos en pacientes oncológicos. Cancerología 2008; 3:71-76.

  19. Cabello-Gutiérrez C, et al. Efecto de una solución electrolizada de superoxidación con pH neutro sobre la infección del virus de influenza A en células MDCK. Rev Inst Nal Enf Resp Mex. 2009; 22(4):280-87.

  20. Paz-García J. Maldonado-Rodríguez A. Días-Reval I. Muñíz J. Rodríguez-Hernández A. Sustitución del uso de solución salina fisiológica como irrigante en el manejo de pacientes sépticos y quirúrgicos por solución electrolizada. Revista Mexicana de Cirugía Bucal y Maxilofacial. 2011; 7(2):46-52.

  21. Velazquez-Meza ME, et al. Evaluation of the Antimicrobial Activity of a Super Oxidized Solution in Clinical Isolates. Microbial Drug Resistance. 2015;21(4):1-6. https://doi. org/10.1089/mdr.2014.0266

  22. Martínez-De Jesús F, et al. Efficacy and safety of neutral pH superoxidised solution in severe diabetic foot infections. Int Wound J. 2007; 4:353-62. https://doi.org/10.1111/j.1742- 481X.2007.00363.x

  23. Criterios de Terminología de Eventos Adversos. Colección Guías Distinguidas, Serie Farmacología 2014; 1(1). https:// www.siicsalud.com/pdf/gd_eventos_adversos_1.1_72114. pdf> (Consultada en marzo 2017).

  24. Martínez-García A, et al. Evaluación de la eficacia de ketoconazol 800 mg-clindamicina 100 mg tabletas vaginales, con ketoconazol 800 mg-100 mg de clindamicina cápsulas vaginales en vaginitis candidiásica y vaginosis. Ginecol Obstet Mex 2011; 79(2):75-85.

  25. Georgiev GZ. Relative Risk Calculator. https://www.gigacalculator. com/calculators/relative-risk-calculator.php> [Consultada en febrero 2019].

  26. Dover SE, et al. Natural antimicrobials and their role in vaginal health: a short review. Int J Probiotics Prebiotics 2008; 3(4):219-30. PMID: 20657710

  27. Petricevic L, Witt A. The role of Lactobacillus casei rhamnosus Lcr35 in restoring the normal vaginal flora after antibiotic treatment of bacterial vaginosis. BJOG 2008; 115:1369-1374. https://doi.org/10.1111/j.1471- 0528.2008.01882.x

  28. Verstraelen H, et al Antiseptics and Disinfectants for the treatment of bacterial vaginosis: A systematic review. BMC Infectious Diseases 2012; 12:148. https://doi. org/10.1186/1471-2334-12-148

  29. Neut C, et al. Topical treatment of infectious vaginitis: effects of antibiotic, antifungal and antiseptic drugs on the growth of normal vaginal Lactobacillus strains. Open Journal of Obstetrics and Gynecology 2015 5:173-80. doi: 10.4236/ojog.2015.53024.

  30. FDA: Office of New Drugs. Manual of Policies and Procedures. Center for Drug Evaluation and Research. October, 2010. MAPP 6010.3 Rev.1. https://www.fda.gov/downloads/ AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/ CDER/ManualofPoliciesProcedures/ UCM080121.pdf> (consultada en enero 2019).

  31. Al-Mushrif S, et alA study of the prevalence of hydrogen peroxide generating Lactobacilli in bacterial vaginosis: the determination of H2O2 concentrations generated, in vitro, by isolated strains and the levels found in vaginal secretions of women with and without infection. J Obstet Gynaecol. 1998; 18(1):63-67. https://doi. org/10.1080/01443619868325

  32. Godínez V, et al. Comparación de la eficacia de la combinación ketoconazol 400 mg + clindamicina 100 mg, con ketoconazol 800 mg + clindamicina 100 mg en vaginitis por Candida y vaginosis bacteriana. Ginecol Obstet Mex 2005; 73:302-7.

  33. Sánchez-Hernández JA, et al. Infección, erosión y úlceras cérvico-vaginales. Acta Científica Estudiantil 2009; 7(4):254-57.

  34. Sellors JW, Sankaranarayanan R. Colposcopy and treatment of cervical intraepithelial neoplasia: A Beginners’ Manual. IARC Press, 2003; 79-84. http://screening.iarc.fr/colpo. php> (consultada en febrero 2019).




2020     |     www.medigraphic.com